; and (C) is not a biological product (as defined in section 351(i) of the Public Health Service Act), unless otherwise provided by the Secretary in the regulations promulgated under subsection (i); . 502. Reporting on supply chains Section 510(j)(3)(A) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(j)(3)(A) ) is amended— (1) by inserting , and the names and unique facility identifiers of the manufacturers of the active pharmaceutical ingredients such person used for the manufacture, preparation, propagation, compounding, or processing of such drug, and the amount of such drug manufactured, prepared, propagated, compounded, or processed using each such active pharmaceutical ingredient from each such manufacturer before the period at the end of the first sentence; and (2) by inserting after the first sentence the following: In addition to the reporting required under the preceding sentence, the Secretary may receive voluntary submissions of such information at more frequent intervals. . 503. Reporting on use of new authorities and requirements with respect to drug shortages Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on— (1) the extent to which the Secretary has implemented the authorities and requirements under sections 506C(g), 506C(j), 506E(d), 510(j)(3), and 704(b)(2) ( 21 U.S.C. 356c(g) , 356c(j), 356e(d), 360(j)(3), 374(b)(2)) of the Federal Food, Drug, and Cosmetic Act, as amended by sections 3111 and 3112 of the Coronavirus Aid, Relief, and Economic Security Act ( Public Law 116–136 ), including— (A) specific examples of uses of such authorities and requirements; and (B) an assessment of the extent to which such authorities and requirements have helped mitigate drug shortages